Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

12 févr. 2020 12h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Artificial Intelligence Antibody Drug Development Collaboration with MAbSilico

Agreement capitalizes on artificial intelligence and deep learning to develop therapeutic monoclonal antibodies, including novel bispecific antibodies (BiCKI® platform)Collaboration runs for 3 years...
14 janv. 2020 02h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Issuance of a New Patent in Japan for Tedopi® on Inducing Early T-Lymphocyte Memory Response

NANTES, France, Jan. 14, 2020 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that the Japanese Patent Office has issued a new patent family related to...
02 déc. 2019 12h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Positive Results from Phase 1 Clinical Study of Anti-IL-7 Receptor Antagonist OSE-127

Planned Phase 2 Studies in Ulcerative Colitis and Sjögren's Syndrome to Start in 2020 NANTES, France, Dec. 02, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE)...
27 nov. 2019 12h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics and HalioDx Collaborate to Perform Immune Biomarker Exploratory Work during Atalante 1 Phase 3 Clinical Trial of Tedopi® in Non-Small Cell Lung Cancer

NANTES, France and MARSEILLE, France, Nov. 27, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), a clinical-stage biotechnology company focused on developing...
11 nov. 2019 02h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Presented Positive Correlation Between Neoepitope Response and Increased Survival for NSCLC Patients Treated with Tedopi®

NANTES, France, Nov. 11, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), today announced that new clinical and preclinical data on its products in immuno-oncology -...
07 nov. 2019 12h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Licensing Deal for Neoepitope Combination Tedopi® in Korea with Chong Kun Dang Pharmaceutical Corporation

NANTES, France, Nov. 07, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), today announced a new licensing deal with Chong Kun Dang (CKD) Pharmaceutical Corporation...
30 sept. 2019 02h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Presents New Preclinical Data on its Novel Bispecific Checkpoint Inhibitor (BiCKI®) Platform Targeting PD-1 and Cytokines to Overcome Tumor Resistance to Checkpoint Inhibitor Blockade

NANTES, France, Sept. 30, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Euronext: OSE) presented new data on its BiCKI® platform at the International Cancer Immunotherapy...
18 sept. 2019 12h15 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Receives a Milestone Payment of €5.4 Million From Bpifrance for SIRPα-Antagonist Monoclonal Antibody BI 765063

First-in-Class Myeloid Checkpoint Inhibitor BI 765063* is Currently in Phase 1 Clinical Development in Advanced Solid Tumors in Partnership with Boehringer IngelheimMilestone Endorses OSE’s Business...
05 sept. 2019 12h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Reports First Half 2019 Results and Provides a Corporate Update

Major clinical progress with four differentiated therapeutic programs in immuno-oncology and autoimmune diseases;Received €25 M in milestones from collaborations with Servier and Boehringer...
03 sept. 2019 12h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Receives New European Patent Protection Through 2037 for OSE-703, a Cytotoxic Monoclonal Antibody Targeting IL-7R, in Cancer Patients

NANTES, France, Sept. 03, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Euronext: OSE) today announces the grant of a new patent from the European Patent Office (EPO)...

Page précédente